The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Visby Medical’s instrument-free reverse transcription (RT)-polymerase chain reaction (PCR) Covid-19 test for pooled samples.
The single-use, instrument-free device is intended for use in assessing pooled patient samples in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories.
Visby noted that the Covid-19 test pooling protocol allows high-complexity labs to merge up to five patient samples into a single device for processing.
A negative result indicates that all five people have tested negative for Covid-19, while obtaining a positive result requires further individual testing of all five samples.
By reducing PCR technology to palm-sized dimensions, the Visby Medical platform offers quick and precise results.
The latest EUA expands the previous authorisation for single patient sample testing at the point of care setting.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, this validates the flexibility and adaptability of the innovative Visby Medical palm-sized PCR technology by expanding its proven capabilities from individual, single-use testing to pooled testing.
Visby Medical Affairs director Teresa Abraham said: “With the SARS-CoV-2 virus ravaging the country, Visby remains steadfast in meeting the urgent needs of the community, its partners, and the changing market dynamics with our instrument-free PCR Covid-19 test.
“Thanks to this EUA, laboratories can meet increasing testing demand by analysing up to five patient samples at once, allowing for significantly increased efficiency and significantly decreased testing costs, particularly in low prevalence settings.”
In February, the US Biomedical Advanced Research and Development Authority (BARDA) awarded $12.3m to Visby Medical to accelerate the development of its rapid, single-use Flu-COVID PCR Test.
In a separate development, the FDA has expanded the EUA label for Quanterix’s Simoa SARS-CoV-2 N Protein Antigen Test to incorporate testing with a nasal swab and saliva samples along with asymptomatic serial testing with nasal swab samples.
The test runs on the company’s fully automated high-throughput immunoassay instrument, Simoa HD-X Analyzer.
